SCHEMBL6778083

SCHEMBL6778083

COc1cc(C(CC(=O)O)NC(=O)CNC(=O)c2cccc(NC(=N)N)c2)cc2c1OCO2

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 10/20 0.44
ITGA2B P08514 6/20 0.44
ITGAV P06756 4/20 0.43
ITGA2 P17301 1/20 0.41
ITGB1 P05556 3/20 0.41
ITGA5 P08648 3/20 0.41
ITGB5 P18084 3/20 0.41
ITGB6 P18564 3/20 0.41
ITGB8 P26012 3/20 0.41
ITGA8 P53708 3/20 0.41
MAPT P10636 1/20 0.39
GPR139 Q6DWJ6 2/20 0.39
POLB P06746 1/20 0.39
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7833456 0.91 NPC1 (0.41) ITGB3ITGA2BITGAVMAPTGPR139
SCHEMBL6778100 0.89 ITGB3 (0.42) ITGB3ITGA2BITGAVITGA2ITGB1
SCHEMBL6777052 0.86 ITGB3 (0.59) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL6777988 0.83 GPR139 (0.49) ITGB3ITGA2BITGAVITGA2ITGB1
SCHEMBL6783457 0.83 ITGB3 (0.45) ITGB3ITGA2BITGAVITGA2ITGB1
SCHEMBL6773834 0.80 ITGB3 (0.51) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL242674 0.80 ITGB3 (0.55) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL6778435 0.80 ITGB3 (0.47) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL6773885 0.79 ITGB3 (0.47) ITGB3ITGAVITGB1ITGA5ITGB5
SCHEMBL6779336 0.79 ITGB3 (0.49) ITGB3ITGA2BITGAVITGB1ITGA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed